Business
OWC Pharmaceutical Comments on Israel's Proposed Medical Cannabis Guidelines
OWC Pharmaceutical Comments on Israel's Proposed Medical Cannabis Guidelines.
About this update from Owc Pharmaceutical Research Corp
[{"type":"text","content":"\n\n\n\nOWC Pharmaceutical Comments on Israel's Proposed Medical Cannabis Guidelines\n\n\n\n\n\nOWC Pharmaceutical Comments on Israel's Proposed Medical Cannabis Guidelines\n\"Cannabis for Therapeutic Purposes\" Plan Receiving Mixed Market Reaction, Says Dr. Yehuda Baruch\nPR Newswire\nPETACH TIKVA, Israel, April 12, 2016\n\n\n\nPETACH TIKVA, Israel, April 12, 2016 /PRNewswire/ --\n\nOWC Pharmaceutical Research Corp. (OTCQB: OWCP), (\"OWC\" or the \"Company\"), an Israeli-based developer of cannabinoid-based therapies targeting a variety of different indications, today commented on the proposed change to Israel's medical cannabis regulations. The second country to approve marijuana for medical use (in 2003), Israel is also a leader in cannabis research, making it a popular location for companies like OWC. Dr. Yehuda Baruch, OWC's Director of Research and Regulation, was the first director of the Israeli MMJ program from 2003 - 2013.\n\n     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )\n\n\n     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )\n\n\nThe proposed changes to the existing Cannabis for Therapeutic Purposes (CTP) structure would provide easier access for patients and physicians, however, it does give the government a more intrusive role. The regulations are expected to be voted on by May of this year.\n\nAccording to OWC, among the proposed changes, the primary results would be:\n\n\nEvery grower that can comply with the needed regulation for growing of cannabis will be allowed to grow, however all cannabis harvested would be sold only to the governmental cannabis agency or its delegates.\n\nThe agency will then mix all the harvest in to 9 blends: sativa, indica and a mixed sativa/indica each strain having three strengths: high THC/ low CBD content, medium CBD and THC, and high CBD / low THC. The agency would then produce cannabis oil for end users and further processing by certified companies.\n\nOnly the agency or its agents will be able to deliver cannabis products to selected pharmacies, where licensed patients will then be able buy their cannabis as prescribed by their physician.\n\n\n\nDr. Yehuda Baruch, OWC's Director of Research and Regulations, commented on the proposed program changes, \"The plan revisions are intended to make cannabis more l...